Furthermore, patients with tumor overexpressing TSTA3 have low survival rates.32 Additionally, miR125b regulates cell survival, proliferation, and invasion via the ErbB2/Her2 pathway in breast and endometrial cancers.33,34 Most recently, Incoronato et al. were able to differentiate between BC patients and normal healthy patients based on miR125b levels in their blood.35 Taken together, miR125b has the potential to function as both a druggable target and prognostic marker in BC patients across all subtypes. The gene discussed is ERBB2; the disease is endometrial cancer.